Ophthalmology Stocks
Specialized therapeutic development and medical device manufacturing targeting vision preservation and ocular disease management define this sector. Revenue models transition from clinical-stage research and development milestones to high-margin commercialization of proprietary drug delivery platforms, surgical instrumentation, and corrective lens technology.
As of Oct 23, 2026, Ophthalmology has 49 US-listed companies worth $204B combined. The median member moved +2.2% over the past week; SGP led among the 25 largest at +18.7% and YDES trailed at -16.4%.
Companies in Ophthalmology
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- ALC – Alcon AG, $34.1B
- VTRS – Viatris Inc, $21.2B
- COO – The Cooper Companies, Inc, $11.7B
- GKOS – Glaukos Corp, $10.4B
- BLCO – Bausch + Lomb Corp, $6.2B
- BLTE – Belite Bio Inc ADR, $5.8B
- KOD – Kodiak Sciences Inc, $5.4B
- TARS – Tarsus Pharmaceuticals Inc, $3.3B
- WRBY – Warby Parker Inc, $3.2B
- VRDN – Viridian Therapeutics Inc, $2.5B
- BHC – Bausch Health Companies Inc, $2.4B
- OCUL – Ocular Therapeutix Inc, $1.7B
- EYE – National Vision Holdings Inc, $1.4B
- OMER – Omeros Corporation, $1.2B
- HROW – Harrow Health Inc, $1.1B
- STAA – STAAR Surgical Company, $1.1B
- MGTX – MeiraGTx Holdings PLC, $955M
- SGP – SpyGlass Pharma, Inc., $792M
- ANNX – Annexon Inc, $726M
- FDMT – 4D Molecular Therapeutics Inc, $711M
- AURA – Aura Biosciences Inc, $678M
- YDES – YD Bio Ltd, $477M
- RGNX – Regenxbio Inc, $473M
- SGHT – Sight Sciences Inc, $467M
- OCS – Oculis Holding AG Ordinary shares, $461M
- IRD – Opus Genetics, Inc., $318M
- SRZN – Surrozen Inc, $276M
- OCGN – Ocugen Inc, $265M
- ABEO – Abeona Therapeutics Inc, $252M
- LCTX – Lineage Cell Therapeutics Inc, $251M
- LFCR – Lifecore Biomedical Inc., $248M
- RXST – Rxsight Inc, $203M
- NBP – NovaBridge Biosciences, $158M
- OTLK – OUTLOOK THERAPEUTICS INC, $127M
- LENZ – LENZ Therapeutics Inc, $102M
- OKYO – OKYO Pharma Limited, $77.1M
- LNSR – LENSAR Inc, $77M
- KLRS – Kalaris Therapeutics, Inc., $56.2M
- ALDX – Aldeyra The, $42.2M
- EYPT – EyePoint, Inc, $34M
- ABVC – ABVC Biopharma Inc, $26.7M
- IRIX – IRIDEX Corporation, $14.3M
- KPRX – Kiora Pharmaceuticals Inc, $10.9M
- TOVX – Theriva Biologics Inc., $9.9M
- PTN – Palatin Technologies, Inc. Common Stock, $9.9M
- CUBT – Curative Biotechnology Inc, $8.4M
- KALA – Kala Pharmaceuticals Inc, $3.7M
- PRFX – Painreform Ltd, $3.5M